Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). The preclinical profile of TR-701 has been documented in a series of presentations at the recent ICAAC conference and can be accessed at the Trius website. Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Market Research Future has a half cooked research report on Global Wound ... and expected to continue its growth by the end of 2022. ... Wound Closure ... 2019 and reaching a value of 13 billion by 2019 and 21 ... Wound Closure Device Market has been growing rapidly and is expected to ...
(Date:1/24/2017)... -- When tragedy strikes, victims often can,t communicate, and first responders ... and who back home is wondering about them. ... safety of their family and friends, while helping first responders get ... crisis. ... find yourself or your family in one of these situations, BioToo ...
(Date:1/24/2017)... , Jan. 24, 2017 Data4Cure, Inc. today ... using its Biomedical Intelligence® Cloud - a semantic data-driven ... multitude of genomic, molecular and clinical data that are ... at a session hosted by Data4Cure at the Precision ... CA. The company,s Biomedical Intelligence® ...
Breaking Medicine Technology:
(Date:1/24/2017)... Columbus, Ohio (PRWEB) , ... January 24, 2017 , ... ... the project's owners, The Zimmerman Companies, has designated The Deco a ... residence must be 55 or older in no less than 80% of occupied units. ...
(Date:1/24/2017)... ... January 24, 2017 , ... The health insurance industry ... Period (AEP) and the Open Enrollment Period (OEP). 2016 was no exception. If ... are witnessing higher deductibles, rising premiums, and few choices with their insurance, which ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... software products, today announced a strategic partnership with Lucidworks , the company ... and analyze their Fusion platform for building powerful enterprise search applications. , Element ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food and Beverage ... Equipment (PACE), at the International Production and Processing Expo (IPPE) in Atlanta, Georgia ... new technology that is used in poultry processing facilities to provide constant, real-time ...
(Date:1/24/2017)... ... 24, 2017 , ... i2i Population Health, a national leader in population health ... , “Cary’s broad financial background is an excellent fit for i2i,” says Justin Neece, ... operations skills we need to take the company to the next level of growth.” ...
Breaking Medicine News(10 mins):